A mouse-based strategy for cyclophosphamide pharmacogenomic discovery.

Genome-wide mapping approaches are needed to more fully understand the genetic basis of chemotherapy response. Because of technical and ethical limitations, cancer pharmacogenomics has not yet benefited from traditional robust familial genetic strategies. We have therefore explored the use of the inbred mouse as a genetic model system in which to study response to the cytotoxic agent cyclophosphamide. Multiple phenotypes have been assessed in response to cyclophosphamide in up to 19 inbred mouse strains, including in vitro hematopoietic progenitor cell toxicity and the mobilization of hematopoietic progenitor cells into peripheral blood. Hematopoietic progenitor cell toxicity in vitro varied 2-fold among strains, whereas in vivo progenitor cell mobilization varied almost 75-fold among strains. Males mobilized more hematopoietic progenitor cells than did females, and the low-mobilization phenotype was dominant to the high-mobilization phenotype in F1 hybrid animals. In an initial attempt to analyze candidate genes, genetic variation was assessed in three cytochrome P-450 genes involved in the metabolism of cyclophosphamide. Resequencing of eight strains identified 26 polymorphisms in these genes that may influence response to cyclophosphamide. Distinct regions of high- and low-polymorphism rates were identified, and two common haplotypes were shared among the strains for each gene that exhibited variation. This phenotypic and genotypic variation among inbred strains provides a framework for cyclophosphamide pharmacogenomic discovery.

[1]  T. Dragani,et al.  Differences in sister chromatid exchange (SCE)-induction in vivo by cyclophosphamide in murine strains. , 1981, Carcinogenesis.

[2]  L. I. Telegin,et al.  [Immunosuppressant effect of cyclophosphamide activated in vitro by liver microsomes from different strains of mice]. , 1981, Biulleten' eksperimental'noi biologii i meditsiny.

[3]  Te Liu,et al.  Immunosuppressant effect of cyclophosphamide activated in vitro by liver microsomes from different strains of mice , 1981 .

[4]  D. Reimer,et al.  Cyclophosphamide-induced in vivo sister chromatid exchanges (SCE) in Mus musculus. III. Quantitative genetic analysis. , 1983, Genetics.

[5]  L. A. Pevnitsky,et al.  Sensitivity to immunodepressant action of cyclophosphamide: analysis of interstrain differences in mice. , 1985, International journal of immunopharmacology.

[6]  D. Hatat,et al.  Most classical Mus musculus domesticus laboratory mouse strains carry a Mus musculus musculus Y chromosome , 1985, Nature.

[7]  R. Parchment,et al.  Roles for In Vitro Myelotoxicity Tests in Preclinical Drug Development and Clinical Trial Planning , 1993, Toxicologic pathology.

[8]  P. Mauch,et al.  Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. , 1993, Blood.

[9]  N Risch,et al.  The Future of Genetic Studies of Complex Human Diseases , 1996, Science.

[10]  L. To,et al.  The biology and clinical uses of blood stem cells. , 1997, Blood.

[11]  C. Scott,et al.  Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. , 1997, Blood.

[12]  D. Link,et al.  The Granulocyte Colony-Stimulating Factor Receptor Is Required for the Mobilization of Murine Hematopoietic Progenitors Into Peripheral Blood by Cyclophosphamide or Interleukin-8 But Not Flt-3 Ligand , 1997 .

[13]  I. Weissman,et al.  Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  O. Colvin.  An overview of cyclophosphamide development and clinical applications. , 1999, Current pharmaceutical design.

[15]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[16]  Colvin Om.  An overview of cyclophosphamide development and clinical applications. , 1999 .

[17]  D. Waxman,et al.  Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. , 2000, Biochemical pharmacology.

[18]  T. Baldwin,et al.  Progenitor cell mobilization by granulocyte colony-stimulating factor controlled by loci on chromosomes 2 and 11. , 2000, Blood.

[19]  D. Link.  Mechanisms of granulocyte colony-stimulating factor-induced hematopoietic progenitor-cell mobilization. , 2000, Seminars in hematology.

[20]  D W Nebert,et al.  Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. , 2000, European journal of pharmacology.

[21]  S Rozen,et al.  Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.

[22]  J. Johnson,et al.  Pharmacogenomics: the inherited basis for interindividual differences in drug response. , 2001, Annual review of genomics and human genetics.

[23]  D. Parent-Massin,et al.  Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.

[24]  E. Oren,et al.  Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. , 2001, JAMA.

[25]  Pui-Yan Kwok,et al.  Primer design for PCR and sequencing in high-throughput analysis of SNPs. , 2002, BioTechniques.

[26]  Hanjing Xie,et al.  Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. , 2002, European journal of pharmacology.

[27]  D. Link,et al.  G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. , 2002, Immunity.

[28]  Hongbing Wang,et al.  The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[29]  Silvia Casati,et al.  In Vitro Tests for Haematotoxicity: Prediction of Drug-induced Myelosuppression by the CFU-GM Assay , 2002, Alternatives to laboratory animals : ATLA.

[30]  J. Watters,et al.  Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy. , 2002, Pharmacogenomics.

[31]  Eric S. Lander,et al.  The mosaic structure of variation in the laboratory mouse genome , 2002, Nature.

[32]  J. Lévesque,et al.  Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. , 2003, The Journal of clinical investigation.

[33]  M. Keating,et al.  Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia , 2003, Cancer.

[34]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[35]  J. Watters,et al.  Using genome-wide mapping in the mouse to identify genes that influence drug response. , 2003, TIPS - Trends in Pharmacological Sciences.

[36]  Pui-Yan Kwok,et al.  Efficient high-throughput resequencing of genomic DNA. , 2003, Genome research.

[37]  L. Y. Telegin,et al.  Immunodepressive effect of cyclophosphamide activatedin vitro by liver microsomes from mice of different lines , 1981, Bulletin of Experimental Biology and Medicine.